Running Oak Capital LLC Grows Holdings in IQVIA Holdings Inc. $IQV

Running Oak Capital LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 20.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 99,077 shares of the medical research company’s stock after purchasing an additional 16,735 shares during the period. Running Oak Capital LLC’s holdings in IQVIA were worth $15,614,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd increased its position in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA during the 1st quarter worth $33,000. Larson Financial Group LLC grew its position in IQVIA by 109.9% during the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after buying an additional 144 shares during the period. Finally, Bruce G. Allen Investments LLC increased its holdings in IQVIA by 178.4% during the first quarter. Bruce G. Allen Investments LLC now owns 323 shares of the medical research company’s stock worth $57,000 after buying an additional 207 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on IQV shares. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Saturday, September 27th. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. UBS Group increased their price target on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Finally, Evercore ISI boosted their price objective on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Eighteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $230.32.

IQVIA Stock Performance

NYSE:IQV opened at $206.84 on Monday. The business’s fifty day moving average is $187.90 and its 200 day moving average is $167.44. The firm has a market cap of $35.16 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.27 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.